The association of statin use with reduced incidence of venous thromboembolism: A population-based cohort study

BMJ Open

Volumn 4, Issue 11, 2014, Pages

  Lassila, Riitta ^a   Jula, Antti ^b   Pitkäniemi, Janne ^a   Haukka, Jari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; CHILD; DRUG USE; EXPLANATORY VARIABLE; FEMALE; FOLLOW UP; HEALTH SURVEY; HOSPITALIZATION; HUMAN; ICD-10; INCIDENCE; INFANT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; SCHOOL CHILD; SEX DIFFERENCE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VERY ELDERLY; YOUNG ADULT; COHORT ANALYSIS; EVALUATION STUDY; PROSPECTIVE STUDY;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM;

EID: 84912043027     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005862     Document Type: Article

References (24)

1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e419S-94S.
2. Squizzato A, Galli M, Romualdi E, et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J 2010;31:1248-56.
3. Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851-61.
4. Biere-Rafi S, Hutten BA, Squizzato A, et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J 2013;34:1800-6.
5. Khemasuwan D, Divietro ML, Tangdhanakanond K, et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010;123:60-5.
6. Akkerman JWN. From low-density lipoprotein to platelet activation. Int J Biochem Cell Biol 2008;40:2374-8.
7. Aromaa A, Koskinen S. Health and functional capacity in Finland. Baseline results of the health 2000 health examination survey. Helsinki, Finland: 2004. http://www.terveys2000.fi/julkaisut/baseline. pdf
8. Heistaro S. Methodology report: Health 2000 survey. Helsinki, Finland: Kansanterveyslaitos, 2008. http://lib.thl.fi:2345/http:/lib.thl. fi:2345/lib4/?PBFORMTYPE=01002&TITLEID=49681&SQS=1: FIN:1::6:50::HTML&PL=0
9. Luotola K, Pietilä A, Zeller T, et al. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. J Intern Med 2011;269:322-32.
10. Juonala M, Viikari JSA, Laitinen T, et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults the cardiovascular risk in young finns study. Circulation 2004;110:2918-23.
11. Kauppi M, Impivaara O, Mäki J, et al. Vitamin D status and common risk factors for bone fragility as determinants of quantitative ultrasound variables in a nationally representative population sample. Bone 2009;45:119-24.
12. WHOCC-ATC/DDD Index. http://www.whocc.no/atc-ddd-index/(accessed 11 Sep 2012).
13. Carstensen B, Plummer M, Laara E, et al. Epi: a package for statistical analysis in epidemiology. 2008. http://www.pubhealth.ku.dk/bxc/Epi/
14. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008;168:656-64.
15. Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 2012;175:250-62.
16. Rahimi K, Bhala N, Kamphuisen P, et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 2012;9:e1001310.
17. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-71.
18. Westerbacka J, Yki-Järvinen H, Turpeinen A, et al. Inhibition of platelet-collagen interaction an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 2002;22:167-72.
19. Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research the importance of restriction. JAMA 2010;304:897-8.
20. Prandoni P, Ghirarduzzi A, Prins MH, et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006;4:1891-6.
21. Prandoni P, Noventa F, Milan M. Aspirin and recurrent venous thromboembolism. Phlebology 2013;28(Suppl 1):99-104.
22. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:131.
23. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009;53:221-31.
24. Casez P, Labarère J, Sevestre M-A, et al. ICD-10 hospital discharge diagnosis codes were sensitive for identifying pulmonary embolism but not deep vein thrombosis. J Clin Epidemiol 2010;63:790-7.